Philip Morris
Increase of Circulating Beta-Endorphin-Like Immunoreactivity Correlates with the Change in Feeling of Pleasantness After Running
Fields
- Author
- Kruger, A.
- Matthaei, H.
- Niemann, J.
- Schmole, M.
- Wildmann, J.
- Area
- WORLDWIDE REG AFFAIRS/LIBRARY
- Type
- PSCI, PUBLICATION SCIENTIFIC
- BIBL, BIBLIOGRAPHY
- Litigation
- Stmn/Produced
- Site
- N403
- Master ID
- 2046398862/0490
- 2046398862-8874 Submission of Phillip Morris Usa and the American Tobacco Company to the Drug Abuse Advisory Committee in Connection with Iots Meeting on 940802 Volume 3.01
- 2046398875 2
- 2046398876-8886 Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Dsm-IV
- 2046398887 3
- 2046398888-8892 Diagnostic and Statistical Manual of Mental Disorders ( Third Edition - Revised) Dsm-III-R
- 2046398893 4
- 2046398894-8897 Diagnostic and Statistical Manual of Mental Disorders ( Third Edition)
- 2046398898 5
- 2046398899-8901 What Makes US Run?
- 2046398902 6
- 2046398903-8931 Chapter 5 the Neurochemical Mechanisms Underlying Nicotine Tolerance and Dependence
- 2046398932 7
- 2046398933-8994 8. The Psychopharmacological and Neurochemical Consequences of Chronic Nicotine Administration
- 2046398995 8
- 2046398997-8999 Establishing A Nicotine Threshold for Addiction
- 2046399000 9
- 2046399001-9006 Intravenous Nicotine Replacement Suppresses Nicotine Intake From Cigarette Smoking
- 2046399007 10
- 2046399008-9013 Daily Intake of Nicotine During Cigarette Smoking
- 2046399014 11
- 2046399015-9022 Stable Isotope Studies of Nicotine Kinetics and Bioavailability
- 2046399023 12
- 2046399024-9060 Biobehavioral Approaches to Smoking Control
- 2046399061 13
- 2046399062-9064 Brief Communication Preference Among Research Cigarettes with Varying Nicotine Yields
- 2046399065 14
- 2046399066-9076 Slip-Ups and Relapse in Attempts to Quit Smoking
- 2046399077 15
- 2046399078-9100 Drug Addiction As A Psychological Process
- 2046399101 16
- 2046399102-9113 Population Characteristics and Cigarette Yield As Determinants of Smoke Exposure
- 2046399114 17
- 2046399115-9123 Smoking History, Cigarette Yield and Smoking Behavior As Determinants of Smoke Exposure.
- 2046399124 Andrews Office Products Capitol Heights, Md (K) 18
- 2046399125-9216 Out of the Shadows Understanding Sexual Addiction Second Edition
- 2046399217 Andrews Office Products Capitol Heights, Md (K) 19
- 2046399218-9220 Morbidity and Mortality Weekly Report Progress in Chronic Disease Prevention Smoking Cessation During Previous Year Among Adults - United States, 900000 and 910000
- 2046399221 Andrews Office Products Capitol Heights, Md (K) 20
- 2046399222-9224 Research Report Can Carrots Be Addictive? An Extraordinary Form of Drug Dependence
- 2046399225 Andrews Office Products Capitol Heights, Md (K) 21
- 2046399226-9233 Running Addiction: Measurement and Associated Psychological Characteristic
- 2046399234 Andrews Office Products Capitol Heights, Md (K) 22
- 2046399235-9252 Goth's Medical Pharmacology
- 2046399253 Andrews Office Products Capitol Heights, Md (K)
- 2046399254-9272 An Analysis of the Addiction Liability of Nicotine
- 2046399273 Andrews Office Products Capitol Heights, Md (K) 24
- 2046399274-9283 Modulation of Nicotine Receptors by Chronic Exposure to Nicotinic Agonists and Antagonists
- 2046399284 Andrews Office Products Capitol Heights, Md (K) 25
- 2046399285-9288 the Effect of Running on Plasma Beta-Endorphin
- 2046399289
- 2046399290 Library Copy: Please Return
- 2046399291 Submission of Philip Morris Usa and the American Tobacco Company to the Drug Abuse Advisory Committee in Connection with Its Meeting on 940802 Volume 3.02
- 2046399292 21 Andrews Office Products Capitol Heights, Md (K)
- 2046399293-9300 Running Addiction: Measurement and Associated Psychological Characteristics
- 2046399301 22 Andrews Office Products Capitol Heights, Md (K)
- 2046399302-9319 Goth's Medical Pharmacology Drug Abuse and Dependence
- 2046399320 23 Andrews Office Products Capitol Heights, Md (K)
- 2046399321-9339 An Analysis of the Addiction Liability of Nicotine
- 2046399340 24 Andrews Office Products Capitol Heights, Md (K)
- 2046399341-9350 Modulation of Nicotine Receptors by Chronic Exposure to Nicotinic Agonists and Antagonists
- 2046399351 25 Andrews Office Products Capitol Heights, Md (K)
- 2046399352-9355 the Effect of Running on Plasma B-Endorphin
- 2046399356 26 Andrews Office Products Capitol Heights, Md (K)
- 2046399357-9375 Shopaholics Serious Help for Addicted Spenders Chapter 3 Nature of Addiction
- 2046399376 27 Andrews Office Products Capitol Heights, Md (K)
- 2046399377-9380 Effect of Transdermal Nicotine Delivery As An Adjunct to Low-Intervention Smoking Cessation Theraphy
- 2046399381 28 Andrews Office Products Capitol Heights, Md (K)
- 2046399382-9394 Measuring Nicotine Dependence: A Review of the Fagerstrom Tolerance Questionnaire
- 2046399395 29
- 2046399396-9419 Tolerance Withdrawal and Dependence on Tobacco and Smoking Termination
- 2046399420 30 Andrews Office Products Capitol Heights, Md (K)
- 2046399421-9426 Methods Used to Quit Smoking in the United States Do Cessation Programs Help?
- 2046399427 31 Andrews Office Products Capitol Heights, Md (K)
- 2046399428-9434 Effect of Transdermal Nicotine Patches on Cigarette Smoking A Double Blind Crossover Study
- 2046399435 32
- 2046399435A Symposium Smoking Cessation: A Comparison of Aided Vs. Unaided Quitters / Attempters. Predictors of Early Relapse.
- 2046399436 33
- 2046399437-9448 Mind Matters How Mind and Brain Interact to Create Our Conscious Lives
- 2046399449 34
- 2046399450-9452 Cigarette Craving, Smoking Withdrawal, and Clonidine
- 2046399453 35
- 2046399454-9456 Psycological and Pharmacological Influences in Cigarette Smoking Withdrawal: Effects of Nicotine Gum and Expectancy on Smoking Withdrawal Symptoms and Relapse
- 2046399457 36
- 2046399458-9463 Crs Report for Congress Cigarette Taxes to Fund Health Care Reform: An Economic Analysis
- 2046399464 37
- 2046399465-9472 22.4 Caffeine and Tobacco Dependence
- 2046399473 38
- 2046399474-9476 Pinball Wizard: the Case of A Pinball Machine Addict
- 2046399477 39
- 2046399478-9492 Reviews Caffeine Physical Dependence: Review of Human and Laboratory Animal Studies
- 2046399493 40
- 2046399494-9498 Brief Report Reactions to Withdrawal Symptoms and Success in Smoking Cessation Clinics
- 2046399499 41
- 2046399500-9505 Nicotine or Tar Titration in Cigarette Smoking Behavior?
- 2046399506 42
- 2046399507-9511 Brief Report Blood Nicotine, Smoke Exposure and Tobacco Withdrawal Symptoms
- 2046399512 43
- 2046399513-9523 Conference Report Involvement of Tobacco in Alcoholism and Illicit Drug Use
- 2046399524 44
- 2046399525-9535 Pharmacologic Basis and Treatment of Cigarette Smoking
- 2046399536 45
- 2046399537-9550 'chocolate Addiction': A Preliminary Study of Its Description and Its Relationship to Problem Eating
- 2046399551 46
- 2046399552-9562 Smoking Cessation Methods: Recommendations for Health Professionals. Advisory Group of the European School of Oncology
- 2046399563 47
- 2046399564-9574 Nicotine Yield As Determinant of Smoke Exposure Indicators and Puffing Behavior
- 2046399575 48
- 2046399576-9581 Psychological Analysis of Establishment and Maintenance of the Smoking Habit
- 2046399582 49
- 2046399583-9586 Seminars in Respiratory Medicine Appetitive Functions and Dysfunctions: Tobacco
- 2046399587 Andrews Office Products Capitol Heights, Md (K)
- 2046399588 Endorphins, Eating Disorders and Other Addictive Behaviors
- 2046399589-9621 the Clinical Phases of Anorexia Nervosa and Their Relevance to Endorphin Addiction
- 2046399622 51
- 2046399623-9632 Pharmacotheraphy for Smoking Cessation: Unvalidated Assumptions, Anomalies, and Suggestions for Future Research
- 2046399633 52
- 2046399634-9641 Risk - Benefit Assessment of Nicotine Preparations in Smoking Cessation
- 2046399642 53
- 2046399643-9650 Should Caffeine Abuse, Dependence, or Withdrawal Be Added to Dsm - IV and Icd - 10?
- 2046399651 54
- 2046399652-9660 Tobacco Withdrawal in Self - Quitters
- 2046399661 55
- 2046399662-9669 Symptoms of Tobacco Withdrawal A Replication and Extension
- 2046399670
- 2046399671-9763 Submission of Philip Morris Usa and the American Tobacco Company to the Drug Abuse Advisory Committee in Connection with Its Meeting on 940802 Volume 3.03 Effects of Abstinence From Tobacco A Critical Review
- 2046399764 57
- 2046399765-9769 Reports From Research Centres - 21 Human Behavioral Pharmacology Laboratory University of Vermont
- 2046399770 58
- 2046399771 Withdrawal Symptoms and Smoking Cessation
- 2046399772 59
- 2046399773-9778 Nicotine Vs Placebo Gum in General Medical Practice
- 2046399779 60
- 2046399780-9783 Prevalence of Tobacco Dependence and Withdrawal
- 2046399784 61
- 2046399785-9790 Signs and Symptoms of Tobacco Withdrawal
- 2046399791 62
- 2046399792-9798 Patterns and Predictors of Smoking Cessation Among Users of A Telephone Hotline
- 2046399799 63
- 2046399800-9820 Current Concepts of Addiction
- 2046399821 64
- 2046399822-9861 the American Academy of Psychiatrists in Alcoholism and Addictions 910000 Annual Meeting
- 2046399862 65
- 2046399863-9915 the Pharmacological Basis of Therapeutics Eighth Edition Chapter 22 Drug Addiction and Drug Abuse
- 2046399916 66
- 2046399917-9953 1 Tobacco Smoking and Nicotine Dependence
- 2046399954 67
- 2046399955-9957 Commentary Trivializing Dependence
- 2046399958 68
- 2046399959-9968 the Favorite Cigarette of the Day
- 2046399969 69
- 2046399970-9971 Overview: Alternative Forms of Pharmacologic Treatment
- 2046399972 70
- 2046399973-9974 British Medical Journal No 6891 Volume 306
- 2046399975 71
- 2046399976-9981 Original Contributors Predicting Smoking Cessation Who Will Quit with and Without the Nicotine Patch
- 2046399982 72
- 2046399983-0019 the Selling of Dsm the Rhetoric of Science in Psychiatry
- 2046400020 73
- 2046400021-0028 the Nosology of Abuse and Dependence
- 2046400029 74
- 2046400030-0035 Use and Misuse of the Concept of Craving by Alcohol, Tobacco, and Drug Researchers
- 2046400035A
- 2046400036-0045 Submission of Philip Morris Usa and the American Tobacco Company to the Drug Abuse Advisory Committee in Connection with Its Meeting on 940802
- 2046400046 75
- 2046400047-0048 What Researchers Make of What Cigarette Smokers Say: Filtering Smokers' Hot Air
- 2046400049 76
- 2046400050-0055 the Use of Flavor in Cigarette Substitutes
- 2046400056 77
- 2046400057-0060 Failure to Support the Validity of the Fagerstrom Tolerance Questionnaire As A Measure of Physiological Tolerance to Nicotine
- 2046400061 78
- 2046400062-0067 Effects of Cigarette Smoking on Electrodermal Orienting Reflexes to Stimulus Change and Stimulus Significance
- 2046400068 79
- 2046400069-0074 Behavioral (Non-Chemical) Addictions
- 2046400075 80
- 2046400076-0078 Nicotine Infused Into the Nucleus Accumbens Increases Synaptic Dopamine As Measured by in Vivo Microdialysis
- 2046400079 81
- 2046400080-0085 the Chemistry of Craving
- 2046400086 82
- 2046400087-0102 the Disease Controversy Revisited: An Ontologic Perspective
- 2046400103 83
- 2046400104-0134 A Psychopharmacological and Psychophysiological Evaluation of Smoking Motives
- 2046400135 84
- 2046400136-0146 Predictors and Reasons for Relapse in Smoking Cessation with Nicotine and Placebo Patches
- 2046400147 85
- 2046400148-0155 Clinical Trials and Therapeutics Nasal Spray Nicotine Replacement Suppresses Cigarette Smoking Desire and Behavior
- 2046400156 86
- 2046400157-0163 Predictors of Smoking Cessation in A Sample of Italian Smokers
- 2046400164 87
- 2046400165-0167 Clarification and Standardization of Substance Abuse Terminology
- 2046400168 88
- 2046400169-0179 the Role of Nicotine in Tobacco Use
- 2046400180 89
- 2046400181-0186 Pharmacoepidemiology and Drug Utilization How the Steady - State Cotinine Concentration in Cigarette Smokers Is Directly Related to Nicotine Intake
- 2046400187 90
- 2046400188-0192 Transdermal Nicotine As A Strategy for Nicotine Replacement
- 2046400193
- 2046400194-0198 Sensory Blockade of Smoking Satisfaction
- 2046400199 92
- 2046400200-0204 Brief Report Subjective Response to Cigarette Smoking Following Airway Anesthetization
- 2046400205 93
- 2046400206-0212 Intervention Strategies for Smoking Cessation the Role of Oncology Nursing
- 2046400213 94
- 2046400214-0219 Reduction of Tar, Nicotine and Carbon Monoxide Intake in Low Tar Smokers
- 2046400220 95
- 2046400221-0234 Long-Term Switching to Low-Tar Low-Nicotine Cigarettes
- 2046400235 96
- 2046400236-0239 Comment Recidivism and Self-Cure of Smoking and Obesity: An Attempt to Replicate
- 2046400240 97
- 2046400241-0249 Recidivism and Self-Cure of Smoking and Obesity
- 2046400250 98
- 2046400251-0263 Public Forum Love: Addiction or Road to Self-Realization, A Second Look
- 2046400264 99
- 2046400265-0274 Pharmacological and Non-Pharmacological Smoking Motives: A Replication and Extension
- 2046400275 100
- 2046400276-0289 Overcoming the Loss of A Love: Preventing Love Addiction and Promoting Positive Emotional Health
- 2046400290 101
- 2046400291-0298 the Health Benefits of Smoking Cessation A Report of the Surgeon General
- 2046400299 102
- 2046400300-0338 the Health Consequences of Smoking Nicotine Addiction A Report of the Surgeon General
- 2046400339 103
- 2046400340-0357 the Health Consequences of Smoking Chronic Obstructive Lung Disease A Report of the Surgeon General Chapter 6. Low Yield Cigarettes and Their Role in Chronic Obstructive Lung Disease
- 2046400358 104
- 2046400359 Smoking and Health Report of the Advisory Committee to the Surgeon General of the Public Health Service
- 2046400360-0369 Chapter 13 Characterization of the Tobacco Habit
- 2046400370 105
- 2046400371-0375 Is Nicotine Use An Addiction
- 2046400376 106
- 2046400377-0391 Nicotine Pharmacodynamics: Some Unresolved Issues
- 2046400392 107
- 2046400393-0400 Craving for Cigarettes
- 2046400401 108
- 2046400402 Smoker Motivation A Review of Contemporary Literature
- 2046400403-0453 Chapter 1 Trends in Cigarette Consumption and the Sociodemographic Structure of the Smoking Population in Developed Industrial Countries
- 2046400454 109
- 2046400462 110
- 2046400463-0469 New Data Note Series - 20 Severity of Dependence: Data From the Dsm-IV Field Trials
- 2046400470 111
- 2046400471-0479 World Health Organization Technical Report Series No. 551 Who Expert Committee on Drug Dependence Twentieth Report
- 2046400480 112
- 2046400481-0489 Cigarette Brand-Switching: Effects on Smoke Exposure and Smoking Behavior
- 2046400490
Related Documents:
Document Images
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Life Sciences, Vol. 38, pp. 997-1003 Pergamon Press
Printed in the U.S.A.
INCREASE OF CIRCULATING BETA-ENDORPHIN-LIKE IMMUNOREACTIVITY
CORRELATES WITH THE CHANGE IN FEELING OF PLEASANTNESS
AFTER RUNNING
Johannes Wildmann+, A~nd Krugern, Matthias Sc~moleII,
JUrgen Niemann , and Heinrich Matthaei
+Max-Planck-Institut fur experimentelle Medizin,
Forschungsstelle Matthaei, Gottingen
Institut fur Sportwissenschaften, Georg-August-Universitat
Gottingen
(Received in final form December 19, 1985)
Summary
Twenty-one male regular long distance runners
participated in two 10 km runs one week apart. Their
3-endorphin-like immunoreactivity (B-EIR) was assayed
in plasma before and immediately after running.
Mood was monitored by an adjective check list
(Eigenschaftsworterliste, EWL) pre- and post-run. (i-EIR
was significantly elevated post-run. Self-reliance and
good mood scored higher after running. Both mood
elevation and plasma (3-EIR increase showed a considerable
individual variability but there was a significant
correlation in the mean values of the two runs between
individual 3-EIR increases (oR-EIR) and the changes of
ratings in feeling of pleasantness (oFP). High o(3-EIR
corresponded to positive mood change post-run.
Introduction
Activities such as exercise and running are followed by a
variety of physiological responses which are mediated in part by
the secretion of catecholamines and several peptide hormones.
Plasma levels of ACTH and B-endorphin have been found to be
elevated concomitantly (1), which in turn might be responsible for
increases, in plasma cortisol and growth hormone as well as
prolactin concentrations (2). On the other hand it could be clear-
ly shown that long lasting physical exercise, for example long
distance running, is followed by acute mood changes (3). Reduction
of state anxiety and increased feeling of pleasantness turned out
to be the most prominent changes (4). There have been successful
attempts to utilize the anxiolytic and antidepressant effects of
running in the treatment of moderately depressed patients (5).
Severe anxiety states and depression belong to the most
malevolent psychologic distress human beings can experience. The
prevalence of anxiety in modern industrial populations is indica-
ted by the high incidence of prescriptions for minor tranquilizers
in western countries. It seems very worthwhile to devote attention
to body own possibilities for regaining psychosomatic health and
0024-3205/86 $3.00 + .00
Copyright (c) 1986 Pergamon Press Ltd.
I

I
I
I
I
I
i
I
I
I
I
I
I
I
I
I
I
I
998 Running and ?food Changes Vol. 38, No. 11, 1986
to learn more about the underlying mechanisms.
The endorphins in particular have been suspected as playing
a part in eliciting mood effects as well as being the cause of
the anecdotically described phenomenon of the "runners high" (6).
Some effects of running and exercise such as iltered pain
perception and miosis are antagonized by naloxone (7, 8). After
acute exercise, high doses of naloxone increased ventilation and
catecholamine titers in plasma which indicates participation of
endogenous opioids in the control of circulating catecholamines
(9). Up to now, little experimental evidence could be provided
that peripheral (3-endorphin plays a part in the emotional altera-
tions mentioned. The failure of antagonzing the behavioral ef-
fects of running using low doses of naloxone was considered an
(l0~ment against the interference of endorphins in this respect
This study attempts to show whether mood change and increase
of plasma 3-EIR after long-distance running are correlated in
each individuals.
Subjects and Methods
Twenty-one male volunteers all of them regular long distance
runners for years participated in this study. They were healthy,
on no medication and non-smokers. They all were used to running
regularly at least once a week. For details see
TABLE I
Specifications and Performance of Volunteers
Age Height Weight Average Years of
running intensive
distance running
(years) (cm)
(kg) per week
(km)
Mean 29,8 180 69,8 56,6 7,4
S. D. 10,7 4,7 5,7 35,9 7,6
range 18 - 62 170 - 185 60 - 78 10 - 115 0,5 - 33
In order to minimize accidental intrapersonal and situa-
tional variabilities every participant completed two 10 km runs a
week apart under equal conditions. For statistical evaluation
average values from both runs were used. The participants were
introduced to the intensions and procedures of the study and gave
their informed consent. They answered a corresponding questionaire
which revealed that every one of them was already experienced the
psychogenic effects of running on their own. Fitness, enhancement
of performance followed by the increase of psychic pleasantness
were most frequently stated as motivation for running regularly.
Reasons of catharsis, social aspects and competitive arguments
were rated as less important.
I

I
I
Vol. 38, No. 11, 1986 Running and Mood Changes 999
I
TABLE II
I
1
I
Participants Motivation Score to Run Regularly
Social Reasons 11 (pts), Catharsis 19, Fitness 29,
Performance 26, Competition 8, Increase of pleasantness 22.
Inquiry scale point system: strongly disagree 2 (pts), agree 1,
undecided 0, disagree -1, strongly disagree -2.
The scores represent the summarized valuations of all partici-
pants.
~ Testing took place between 14.00 and 18.00 hr. The volun-
teers were instructed to run 10 km, i. e. 25 laps on a 400 m all
weather track, up to maximal aerobic capacity. Lap times were
registered to plot individual speed variations. Mood was moni-
,.r tored using the EWL (Eigenschaftsworterliste) scale, an adjective
~ check list. EWL is a multidimensional method for describing the
actual mood state. It was developed in 1961 and was validated by
correlation with other adjective check lists (11). Mood is judged
by agreement or rejection of 123 adjectives given by the test.
~ The items record 14 aspects of mood (activation, concentration,
deactivation, tiredness, mental clouding, extraversion, introver-
sion, self-confidence, elation, excitement, emotional sensivity,
irritation, anxiety, depressive mood and thinking introversion)
, which can be categorized into 6 fields. The field "feeling of
pleasantness", includes the aspects self-confidence and elation,
covering a total of 19 items. According to the authors of the
EWL-list average ratings of the feeling of pleasantness have been
~ proved to be 8 - 10 items, indicating a"normal" mood. The EWL-
questionaire, which defines state of mood, was answered three
times: at rest at home, immediately prior running and 10 min
after running. In addition, a trait personality test (FPI) (12)
was completed at home. Blood samples were drawn by venipuncture
~ immediately before and 7 min after finishing the run and a third
sample was taken 3 hr thereafter.
Blood samples were collected in siliconized glassware placed
~ on ice containing EDTA-Na (9 ug/5 ml whole blood). After
centrifugation (10', 00 C~ plasma samples were frozen and stored
at - 350 C as a source of B-endorphin-RIA. Samples were thawed
only once and assayed in duplicate.
~ R-endorp~hin RIA: For the determination of circulating
R-endor- piin=Tike immunoreactivity (3-EIR) a commercially available
assay kit (INC, Stillwater, USA) was used. It involves extraction
of R-endorphin from plasma by anti-B-endorphin coated sepharose
~ particles. Incubation: 21 hr at 20 C. Phase separation is achieved
by a second antibody method. An internal standard was run with the
assay. The antibody used does not descriminate N-acetyl-B-
endorphin, des-tyr-endorphin and a-endorphin. The assay showed
r neglectible or no crossreactivity with B-lipotropin (< 5 %),
L a-endorphin, y-endorphin, dynorphin, leu- and met-enkephalin, r.~
ACTH and others (none). The range of sensitivity was 0,5 - 80 p ~
mol/l plasma. The intraassay variation was < 10 %. OPb
~ Statistics: For every participant, the a-EIR increases (post ~
~
- ~~
s ~
Cr~:
~
I

I
I
I
I
I
I
I
I
I
I
i
`
'
_
,i
~
~
*
~
1000 Running and Mood Changes Vol. 38, No. 11, 1986
run values minus resting values) and the differences (post minus
pre run) in EWL ratings related to the feeling of pleasantness
were averaged for the two runs.
The Spearman rank coefficient of correlation was used to
describe the connection between the increase of plasma (3-EIR and
mood change after running.
Results
After running a distance of 10 km, which the participants
completed in a mean time of 39 min 11 sec (SD + 5'13 "; range
33'44 "- 55'11" ) plasma 3-EIR was significantly increased
(19.6 +_ 9.2 pmol/1) as compared to pre-run values (4.6 + 2.7
pmol/l P < 0.0001). This result is in accordance with earlier
studies (13, 14, 15). Three hours after finishing the run,
circulating 5-EIR concentrations were found to have returned to
the range of starting (3.2 + 2.0 pmol/1).
Considerable individual variations were observed as far as
resting a-EIR and increase of t3-endorphin titers after running
were concerned, indicated by high standard deviations. The test
retest correlation of the two runs for (3-endorphin increase was
significant at the 0.01 level which highly indicates that the
intra-subject variability is consistant.
TABLE III
Individual Changes of Mood Score (4FP) and (3-EIR Levels (^3-EIR)
i. e. Post-minus Pre-run Values
Subjects IFP
(items) 1./2.
Run ~,Li-EIR
(pmol/1) 1./2.
Run
1 - 2 (- 4/ 0) 7 ( 6 / 8 )
2 8 ( 8/ 8) 23 (21 /25 )
3 13,5 ( 16/ 11) 26,5 (37 /16 )
4 3 ( 0/ 6) 8,25 ( 1 /15,5)
5 0 ( 0/ 0) 14,75 (13 /16,5)
6 7 ( 4/ 10) 11 ( 9 /13 )
7 5 ( 9/ 1) 16,75 ( 7 /26,5)
8 13 ( 14/ 12) 28 (22 /34 )
9 0,5 ( 1/ 0) 17 (21,5/11,5)
10 - 3 (- 1/- 7) 7,25 (12 / 2,5)
11 - 2,5 (- 4/- 1) 16,5 (15 /18 )
12 4 ( 4/ 4) 18,5 (16 /21 )
13 11 ( 121 10) 28,75 (27 /30,5)
14 - 2 (- 1/- 3) 10 (10 /10 )
15 1 ( 0/ 2) 12,75 ( 9 /16,5)
16 - 8,5 (- 8/- 9) 3,5 ( 4 / 3 )
17 - 2 (- 4/ 0) 7,5 ( 7 / 8 )
18 5 ( 8/ 2) 27,5 (34 /21 )
19 2 ( 4/ 0) 23 (24 /22 )
20 3,5 ( 2/ 5) 7,5 ( 1 /13 )
21 1,5 ( 0/ 3) 5 ( 3,5/ 6,5)
All values are means of 2 runs. Single values are given in ~
brackets. ~
~
C=
. ~
Cst
00
~

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Vol. 38, No. 11, 1986 Running and Mood Changes 1001
General feeling of pleasantness, which combines items of the
EWL checklist related to self-confidence and elevated mood,
scored higher post-run'as compared to pre-run. The mean increase
of the two runs for all subjects tested was 2.79 + 5.54 from a
total of 19 items. Again considerable individual differences were
striking (see S. D.), therefore the increase did not reach sig-
nificance.
Item alterations (~IFP = post-run minus pre-run values)
grouped under self-confidence and elevated mood and the cor-
responding increase of plasma (i-EIR (af3-EIR = post-run minus pre-
run titers) are given for every individual subject in Table III
as mean values of the two runs.
The Spearman rank coefficient of correlation rs fur mean
Af3-EIR and mean oFP is 0.7377 (P < 0.001, Fig. 1).
0-1
Ln
E
10
~
.~
N
N
(D
C
C
d
O
a
0
~
0
rn
C
~
v
.
L-10 0 15 30
A f3-endorphin IR (pmot / 1)
FIG. 1
Graphic presentation of the correlation between Al3-EIR and oFP
for each participant as means of 2 runs.
Discussion
Long distance running (10 km) is followed by an increase in
3-endorphin IR and changes in mood. Both parameters showed high,
inheritant individual variations. In addition to individual pre-
I

I
I
I
I
I
I
I
I
I
I
I
1002 Running and Mood Changes Vo1. 38, No. 11, 1986
dispositions, cognitive influences and esthetic sensations per-
ceived during running may vary and influence chemical factors
such as opioid peptides stimulated by long-distance running.
There are no significant or obvious relations to performance, age,
or years of intensive training as could be shown before (15).
In this study a correlation between circulating !3-EIR in-
crease and feeling of pleasantness could be clearly demonstrated
for the first time. In an earlier investigation a similar corre-
lation did not prove to be significant, partly because of the
insufficient number of participants (16) as well as substancial
inter-subject variability. Arguments against the involvement of
endorphinergic system in mood elevation after running were put
forward by Markoff and co-workers (10), because of their failure
to antagonize these effects. However, these investigators may not
have used a dose large enough to block endorphin activity, and
they did not measure central or peripheral endorphin levels.
On the other hand, at least three different types of opioid
receptors were suggested by physiological studies (15), just as
opioid receptor binding studies demonstrated the presence of
multiple opioid receptors (16). Only the .:-receptor, which
interacts with morphine-like drugs, is effectively blocked by
naloxone (17). For antagonism of other ligands much higher
naloxone concentrations are required.
u-receptors seem to be related to analgesia and they mediate
the formation of miosis. Behavioural and mood effects such as
euphoria and mania are thought to be triggered by putative
o-receptors. Reduction of pain sensitivity after running and
exercise and its antagonism by the u-receptor antagonist naloxone
is well documented (7, 20). Also u-receptor-linked development
of miosis in humans after running was naloxone reversible (8).
But in the light of these considerations, naloxone concentrations
employed to antagonize mood changes (10) appear far too low to
become operative on a-receptors. Also see Ref. 21 for more
detailed comments on this study.
No simple conclusion, may be drawn as to the relationship
t between endorphinergic alterations and emotional elation a
/ consequence of the correlation between R-endorphin and mood; nor
is it to be interpreted as a direct connection of these two facts.
Moreover, up to now there is no clear evidence that peripheral
~, endorphins possess central actions or even whether they covary
-/s with the activity of the central endorphinergic system. Long dis-
tance runners constitute a unique population, therefore, results
cannot be generalized to all subjects. The group studied had been
running an average of 7 years and changes in peptide storage,
~ release and feedback might have occured over time.
As indicated by the motivation scores (see Table II),
participants of this study could possibly represent a certain
` selected group of individuals, who are above average in their
s ability to experience the psychogenic effects of running because
of specific physiological preconditions which indirectly induce ~
them to run. ~
~ All in all, general statements can only be made when possible ~
interactions of basicindividual psychological parameters have been ~
~
. C)
~
~ o

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
ol. 38, No. 11, 1986 Running and >iood Changes
investigated.
Acknowledgment
1003
The skillfull technical help of Mrs. W. Kopp is gratefully
acknowledged.
References
1. F. FRAIOLI, C. MORETTI, D. PAOLUCCI, E. ALICICCO, F. CRES-
CENZI and G. FORTUNIO. Experientia 36 987-989 (1980).
2. Y. KATO, Y. JWASAKI, H. ABE, S. OHGO and H. IMURA. Proc Soc
Exp Biol Med 158 431-436 (1976).
3. J.A. BLUMENTHTC; R.S. WILLIAMS, T.L. NEEDELS and A.G.
WALLACE. Psychosom Med 44 529-536 (1982).
4. D.P. NOWLIS and N. GREENgERG. Percept Mot Skills 49 1001-
1002 (1980).
5. J.H. GREIST, M.H. KLEIN, R.R. EISCHENS, J. FARIS, A.S. GUR-
MAN and W.P. MORGAN. Compr. Psychiatry 20 41-54 (1979).
6. C. PARTIN. JAMA 249 21 (1983).
7. R.J. HAIER, K. QUAT15 and J.C. MILLS. Psychiatry Res 5 231-
232 (1981).
8. M. ALLEN, J. THIERMAN and D. HAMILTON. Can J Appl Sport Sci
8 98-103 (1983).
9. A. GROSSMAN, P. BOULON, P. PRICE, P. DRURY, K. LAM, K.G.M.M.
ALBERTI, T. TURNER, G.M. BESSER and J. SUTTON. Clin Sci
67 483-492 (1984).
10. 77A. MARKOFF, P. RYAN and T. YOUNG. Med Sci SPT 14 11-15
(1982). `
11. W. JANKE and G. DEBUS. Eigenschaftswbrterliste (EWL),
Verlag fUr Psychologie Dr. C.J. Hogrefe, Gottingen (1978).
12. J. FAHRENBERG, H. SELG and R. HAMPEL. Das Freiburger Per-
sbnlichkeitsinventar (FPI). Verlag fiir Psychologie Dr. C.J.
Hogrefe, Gottingen (1973).
13. J. DEARMAN and K.T. FRANCIS. J Sport Med 23 30-38 (1983).
14. W.M. BORTZ, P. ANGWIN, I.N. MEFFORD, M.R. BUARDER, N. NOYCE
and J.D. BARCHES. N Engl J Med 305 466-467 (1981).
15. W.D. COLT, S.L. WARDLOW and A.C.-77ANTZ. Life Sci 28 1637-
1640 (1981). -
16. P.A. FARREL, W.K. GATES, M.G. MAKSUD and W.P. MORGAN. J
Appl Physiol 52 1245-1249 (1982).
17. W.R. MARTIN, hG. EADES, J.A. THOMPSON, R.E. HUPPLER and
P.E. GILBERT. J Pharmacol Exp Ther 197 517-532 (1976).
18. L.E. ROBSON, S.J. PATERSON and H.W. MTERLITZ. New York
Plenum Press, Vol. 17 p 13-80 (1983).
19. K.J. CHANG and P. CUATRECASAS. J Biol Chem 254 2610-2618
(1979). . -
20. B.C. SHYN, S.A. ANDERSSON and P. THOREN. Life Sci 30 833-
840 (1982).
21. L.S. BERK and S.A. TAN. Med Sci SPT 14 V (1982).
I
